Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2Phase 1/2 1

Status

Completed 4Terminated 1

Sponsor Class

OTHER 6INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Gynecologic 1

Conditions

Prostatic Neoplasms 47Breast Neoplasms 6Leiomyoma 5Neoplasms 4Adenocarcinoma 2Uterine Neoplasms 1Urogenital Neoplasms 1Prostatic Diseases 1Premenopausal Breast Cancer 1Polycystic Ovary Syndrome 1Neoplasms, Glandular and Epithelial 1Neoplasm Metastasis 1Myofibroma 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lower Urinary Tract Symptoms 1Infertility 1Hodgkin Disease 1Hereditary Sensory and Autonomic Neuropathies 1Genital Neoplasms, Male 1Carcinoma 1Breast Neoplasms, Male 1Advanced Prostate Cancer 1Advanced Prostate Adenocarcinoma 1

Interventions

telapristone acetate 18vilaprisan 12relugolix 11estradiol, norethindrone drug combination 9asoprisnil 9Estradiol 8elagolix 7Uterine Myomectomy 7ulipristal acetate 6Norethindrone Acetate 6Leuprolide 5linzagolix 4Uterine Artery Embolization 3Sugars 3ulipristal 2Progestins 2Mifepristone 2epigallocatechin gallate 1carbetocin 1Vitamin D 1Vitamin B 6 1Therapeutics 1Standard of Care 1Sodium Chloride 1Robotic Surgical Procedures 1Radiofrequency Ablation 1Progesterone 1Microbial Collagenase 1Megestrol Acetate 1Medroxyprogesterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
INDUSTRY × Leiomyoma × Leuprolide × Clear all
NCT05440383 2025-03-14

A Clinical Study of KLH-2109 in Uterine Fibroids Patient With Menorrhagia

Kissei Pharmaceutical Co., Ltd.

Phase 3 Completed
287 enrolled

Leiomyoma

NCT02655237 2019-03-22

A Phase 3 Study to Evaluate the Efficacy and Safety of Relugolix (TAK-385) 40 mg Compared With Leuprorelin in the Treatment of Uterine Fibroids

Takeda

Phase 3 Completed
281 enrolled 37 charts

Leiomyoma

NCT00683917 2014-08-21

Pharmacokinetics, Safety and Efficacy Study of Proellex in Pre-menopausal Women With Symptomatic Uterine Fibroids

Repros Therapeutics Inc.

Phase 2 Terminated
10 enrolled 1 chart

Leiomyoma

NCT01069094 2014-06-30

A Study of Progenta (CDB-4124) in Pre-menopausal Women With Symptomatic Leiomyomata

Repros Therapeutics Inc.

Phase 1/2 Completed
29 enrolled

Leiomyoma, Myofibroma

NCT00776074 2010-06-22

A Pharmacodynamic Study of Leuprorelin Gelatin-Free Formulation in Female Subjects With Uterine Fibroids.

Takeda

Phase 2 Completed
80 enrolled
Gynecologic

Leiomyoma, Uterine Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡